Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

This important work advances our understanding of DNA methylation and its consequences for susceptibility to DNA damage. This work presents evidence that DNA methylation can accentuate the genomic ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China ...

The combination therapy of bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF) was both tolerable and produced virologic ...

"It's incredible, and a big surprise, that the same infection that caused so much devastation can help create a ...

In a remarkable medical breakthrough, doctors have successfully used stem cells to treat a debilitating eye condition that ...

The FDA has cleared the research organization's investigational new drug application, allowing it to start clinical tests of the experimental treatment DT2-SCT.

Investigators at Dana-Farber Cancer Institute are opening a new clinical trial to evaluate a novel type of immune cellular ...

Immunotherapy, which enhances the immune system's T cell response to eliminate cancer cells, has emerged as a key approach in ...

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...